WO1988007371A2 - Prevention and treatment of the deleterious effects of exposing skin to the sun, and compositions therefor - Google Patents
Prevention and treatment of the deleterious effects of exposing skin to the sun, and compositions therefor Download PDFInfo
- Publication number
- WO1988007371A2 WO1988007371A2 PCT/US1988/001036 US8801036W WO8807371A2 WO 1988007371 A2 WO1988007371 A2 WO 1988007371A2 US 8801036 W US8801036 W US 8801036W WO 8807371 A2 WO8807371 A2 WO 8807371A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ultraviolet radiation
- inhibit
- compound
- methyl ester
- delayed hypersensitivity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
Definitions
- Skin cancer now ranks as the number one form of cancer in the United States today. The increase in the occurrence of skin cancer ranks second only to the increase of lung cancer in women.
- Some forms of skin cancer can be attributed to chronic, year-round exposure to the ultraviolet radiation of the sun.
- Malignant melanoma a dangerous form of skin cancer because of the speed with which it can spread through the body, is thought to stem from "severe episodic sunburn".
- This type of sunburn is described as a sunburn obtained intermittently with no base tan. It occurs when people go out and get burnt once or twice a year; and then repeat this pattern year after year. It is frequently found in people who live in cold climates and who vacation in midwinter in warmer regions. There is no gradual exposure to the sun. They go into the sun with zero exposure, so that the skin has no chance to protect itself, and end up wi th severe sunburn.
- UV light which causes the sunburn likewise induces other changes in the skin which are believed to predispose, or lead, an individual to skin cancer.
- Such exposure can cause tumor graft tolerance and suppress delayed hypersensitivity (DH) [Parrish, J.A., ed. "The Effect of Ultraviolet Radiation on the Immune System", Johnson and Johnson Baby Products Company.].
- DH delayed hypersensitivity
- Irradiated mouse skin secretes low molecular weight protein that stimulates suppressor T cells in the spleen [Swartz, J. Invest.
- ultraviolet radiation suppression of delayed hypersensitivity can prevent rejection of ultraviolet radiation exposed skin, at the risk of the long-term consequence of elevated skin tumor susceptibility. It would be advantageous to eliminate this effect in order to reduce or eliminate the possible long-term consequence of skin cancer in individuals who have sustained recent sun exposure.
- the 21-oic acid methyl ester of triamcinol one acetonide (TAme), other compounds affecting the arachidonic acid cascade and other known synthesis inhibitors, and topical compositions thereof can be utilized to inhibit ultraviolet radiation suppression of delayed hypersensitivity in the epidermis of individuals exposed to ultraviolet radiation, thereby reducing or obviating the carcinogenic effects of ultraviolet radiation by administering topically to the affected area the compound or a composition thereof in an amount effective to inhibit the ultraviolet radiation suppression of delayed hypersensitivity without systemic effects.
- TMAme triamcinol one acetonide
- the present invention relates to the use of tr iamcinolone acetonide 21-oic acid methyl ester, compounds affecting the arachidonic acid cascade and other known synthesis inhibitors, and topical compositions thereof to reduce or obviate the carcinogenic effects of ultraviolet radiation.
- this invention provides a method of inhibiting ultraviolet radiation suppression of delayed hypersensitivity in the epidermis of individuals exposed to ultraviolet radiation utilizing tri amcinol one acetonide 21-oic acid methyl ester, compounds affecting the arachidonic acid cascade and other known synthesis inhibitors, and topical compositions thereof without systemic effects.
- the glucocorticoid utilized in the present invention is the 21-oic acid methyl ester of triamcinolone acetonide. It can be conveniently prepared by the synthetic routes detailed in Gorsline et al., Endocrinology, 116, pp. 263-273 (1985).
- the active glucocorticoid, triamcinolone acetonide 21-oic acid methyl ester can be utilized in the method of the present invention alone, or more conveniently, formulated into a topical composition suitable for dermatological use.
- Such formulations comprise the triamcinol one acetonide 21-oic acid methyl ester in a vehicle suitable for topical administration to the epidermis of an individual in need of therapy for exposure to ultraviolet radiation or sunburn.
- the compounds affecting the arachidonic acid cascade and the prostaglandin synthesis inhibitors include, but are not limited to, aspirin, ibuprofen, indomethacin, salicylic acid, phenyl butazone, sulf inpyrazon and sulindac. These compounds may be formulated into pharmaceutical compositions with known pharmaceutically acceptable carriers for therapeutic administration.
- compositions as are useful with the glucocorticoid of the present invention are exemplified by ointments, creams, lotions, aerosols, gels or soaps.
- compositions will normally be based upon standard dermatological carriers which are pharmaceutically acceptable and cosmetically elegant, such as those selected from pharmaceutically acceptable polyalkylene glycols, isopropanol, gelatin, benzyl alcohol, gums, glycerol and petrolatum.
- the compositions may contain preservatives, aerosol propellants, such as hydrocarbons, and coloring, thickening, suspending, dispersing, emulsifying, wetting, stabilizing and buffering agents.
- compositions of the present invention may be utilized to treat the epidermis of individuals who have been exposed to ultraviolet radiation in potentially carcinogenic quantities. The amount of such exposure may vary from individual to individual and it is envisioned that a physician or other treatment administrator will consider factors such as the individual's age, weight, complexion and degree of exposure in administering the proper dosage. Treatment is envisioned to be accomplished by applying the topical composition to completely cover the affected area.
- the dosage of the compounds is preferably in the range of 0.01 mg/m 2 to about 100 mg/m 2 skin surface area.
- the predicted frequency of application is once or twice daily, but this may of course be varied depending upon the particular individual involved.
- the method of treatment utilizing the compounds of this invention to treat individuals exposed to ultraviolet radiation comprises administering one or more of the compounds or a topical composition thereof to an individual in need of such therapy in an amount sufficient to inhibit the ultraviolet radiation suppression of delayed hypersensitivity in the epidermis thereby reducing or obviating the carcinogenic effects of the ultraviolet radiation.
- the unique properties of the active ingredient allow treatment of the epidermis exposed to ultraviolet radiation without concommitant systemic effects. Since these compounds act only upon the epidermis in this therapeutic context, they are uniquely suited to the method of treatment of the present invention.
- the method of the present invention will inhibit the ultraviolet suppression of delayed hypersensitivity in the epidermis.
- the adminstration of the triamcinol one acetonide 21-oic methyl ester will prevent the induction of suppressor T lymphocytes which lymphocytes are responsible for the prevention of rejection of tumor tissue.
- the epidermis will thus continue in a normal fashion which would thus allow the rejection of tumor tissue and prevent the carcinogenic effects of the ultraviolet radiation exposure.
- the elicited response to treatment with the compounds of the present invention in the individual's epidermis will be rejection of the sunburned skin.
- This rejection will result in intense infiltration, hyperproliferation and purulent crusting in the epidermis of the individual.
- This is a manifestation of a normal immune system which is indicative of the fact that the ultraviolet radiation suppression of delayed hypersensitivity has been successfully blocked.
- the so-treated individual will have increased his chances of rejecting to neoplasm and thus reduce or obviate his chances of sustaining ultraviolet radiation carcinogenesis.
- TAme and the other compounds of the present invention prevent the UV suppression of delayed hypersensitivity at the site of irradiation.
- TAme may block all cell responses by poisoning cell machinery or by vasoconstriction.
- TAme it has been noted as having no discernible effect on unirradiated skin, but enhanced markedly neutrophilic infiltration and epidermal hyperplasia in UV-irradiated skin.
- TAme directly prevents an epidermal signal inducing ultraviolet radiation suppression of delayed hypersensitivity.
- Possible sources include the Langerhans cell, whose functional properties appear to be altered substantially by glucocorticoids; the keratinocyte; or arachidonic acid metabolism to prostaglandin in the skin, of which the last appears to be confirmed to date. Other explanations are possible. While there is no evidence that a steroid applied after irradiation would influence photocatalyzed conversion of urocanic acid to a suppressing substance, possible effects on its release or subsequent metabolism cannot be excluded.
- the infiltrate and hyperplasia were absent in the TAme only group, these were not caused by simple drug effects such as irritation. However, the response did not resemble microscopically either graft rejection or delayed hypersensitivity, in that mononuclear cels were not abundant.
- the polymorphonuclear infiltrate could be a response to cell breakdown products or to bacterial antigens. Conceivably, the neutrophils or irradiated epidermal cells secrete a growth factor. Gamma interferon secretion from macrophages or T-lymphocytes has been implicated in acanthotic changes during delayed hypersensitivity reactions, see Kaplan et al., Proc. Nat. Acad. Sci.
- TAme-treated epidermis was ineffective at provoking or suppressing cell-mediated immunity when untreated epidermis was effective.
- TAme did not cause direct toxicity nor did it affect sensitization or challenge at a distal site.
- mice aged about 4 months are secured from the Rockefeller University colony established in December, 1983, from NIH Balb/CAnN stock.
- DN CB 1-chloro-2,4-dinitrobenzene
- TA triamcinoone acetonide
- Sigma TAme
- Irradiation To handle the irradiation of mice in groups, holes 2 cm on a side are cut in a cardboard mask which is then set above a bank of two GEG15T8 high pressure Hg lamps emitting primarily at 254 nm. This lamp minimizs possible systemic effects of irradiation. 254 nm light penetrates the epidermis less deeply than sunlamp radiation, which is more commonly used to study UV supression of delayed hypersensitivity. Incident dose is 12 W/m 2 as measured by an acti nometrically calibrated Black Ray model J-225 shortwave UV monitor.
- Steroid treatment Forty micrograms of TA or TAme, dissolved at a concentration of 0.2% in absolute USP ethanol, is spread over the UV-irradiated site and spread with a microliter pipette (Rainin Pipetman P-20); the same dosage being used for both compounds since they differ only by a methyl group. ( TA is used to compare results with a glucocorticoid having undesirable systemic effects).
- DNCB Applications Animals are shaved on the lower back to expose about 4 cm 2 skin. For experimental sensitization, 20 microliters of a 2% solution of DNCB in ethanol are applied to this shaved site. To ascertain the degree of delayed hypersensitivity; four days after the first sensitizing application, 5 microliters of DNCB freshly dissolved to 2% in ethanol are applied to the inner and outer aspects of each animal's left ear (total 200 micrograms). Ear thickness is measured just prior to this challenge and at 24 hour intervals thereafter with the aid of a dissecting microscope and a dial engineer's caliper. Histology: Abdominal skin, fixed in formalin, is embedded in paraffin; microtome sections is stained with hematoxylin-eosin.
- mice from a colony are caged in six groups. Three of the groups of mice are exposed to 4 kJ/m 2 254 nm light; others are shaved but not irradiated. Immediately following ultraviolet exposure (day 0), mice are painted with steroid or with vehicle (ethanol) at the site of irradiation. This treatment is repeated 3 times at approximately 24 hour intervals, then discontinued. On day 5, the lower back of each animal is shaved to expose about 4 cm 2 skin. Animals to be sensitized are painted at this site with 1-chloro-2, 4-dinitrobenzene (DNCB) in ethanol, and this treatment is repeated 24 hours later (day 6).
- DNCB 1-chloro-2, 4-dinitrobenzene
- the test for delayed hypersensitivity response is maximal four days after the first sensitizing tratment (not shown).
- Day 9 is chosen to challenge for contact sensitivity by application to the left ear of 1-chloro-2,-4-dinitrobenzene in ethanol.
- Ear swelling is measurable on day 10, but it peaks on day 11, 48 hours following challenge.
- mice The data for this experiment are summarized in Table I, where the average for each group of mice is shown as the ratio of left and right ear thicknesses.
- the average thickness of the left and right ears for most groups was 0.24 mm on day 9.
- the sensiti zation causes the 1-chloro-2,4-dinitrobenzene treated skin to thicken and become indurated. This response is most pronounced in the controls, the TAme only, and the ultraviolet radiation + TAme groups.
- ears swell according to group.
- the swelling is accompanied by a mild erythema, and a visual estimate of the extent of the erythema and swelling correlates well with the caliper measurements:
- Ears of sensitized controls swell to about twice their normal thickness.
- Ears of unsensitized mice do not swell.
- the response measured here is therefore a consequence of delayed hypersensitivity rather than primary irritation, which, at higher 1-chloro-2,4-dinitrobenzene concentrations than those used here, also produces ear swelling. For instance, 1-chloro-2,4-dinitrobenzene irritation is measurable in the controls.
- the triamcinolone acetonide only group was strongly suppressed for delayed hypersensitivity.
- the UV + TA group exhibited a weak degree of delayed hypersensitivity comparable to that in the UV only group.
- Mice treated with triamcinolone acetonide 21-oic acid methyl ester but not with UV on the other hand, exhibited normal delayed hypersensitivity.
- Triamcinolone acetonide gains access to the circulation and thus may act at a distance.
- triamcinolone acetonide could act at the spleen or at the skin to prevent delayed hypersensitivity.
- Testing for the effect of TAme on delayed hypersensitivity at the site of sensitization is as follows: On day 0, the shaved back skin of C57B1/K6S mice are painted with 1-chloro-2,4-dinitrobenzene; with TAme; or with both compounds. On day 6, the animals are tested for delayed hypersensitivity by application of 1-chloro-2,4-dinitrobenzene or of TAme + DNCB. The data obtained shows that TAme prevents delayed hypersensitivity when applied to the back at the time of sensitization and also prevents ear swelling when applied to the ear at the time of challenge.
- mice of the experiment shown in Table I are killed on day 3 or 12 for histological examination of the UV-exposed portion of their abdominal skin.
- the evaluation is summarized in Table II.
- the skin of UV only mice on day 3 contained a diffuse dermal infiltrate, consisting of about 90% neutrophils and 10% monocytes and macrophages.
- the inflammatory changes were not accompanied by erythema and were in other ways characteristic of UV-exposed mouse skin [Photobiol. 37 , pp 623-631 (1983)].
- the dermis of TAme-treated, UV-irradiated mice was infiltrated by polymorphonucl ear leukocytes. Macroscopically, there was induration and purulent crusting.
- Sensitized 9 24.2 1.3 24.4 1.4 0.99 -0.2 control 10 42.6 3.6 26.9 1.5 1.58 15.6
- Triamcinolone acetonide 21-ennoic acid methyl ester other compounds affecting the arachidionic acid cascade a other known synthesis inhibitors, and topical and pharmaceutical compositions thereof are utilized in a method of treati ultraviolet radiation exposed skin to inhibit ultraviolet radiation suppresion of delayed hypersensitivity in the epiderm thereby reducing or obviating the carcinogenic effects of the sunburn.
- Formulations of the triamcionolone acetonide 2 ennoic acid methyl ester preferably contain about 0.005 to 1.0 percent by weight of the active ingredient.
Abstract
Description
Claims
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3076487A | 1987-03-25 | 1987-03-25 | |
US16154288A | 1988-02-29 | 1988-02-29 | |
US161,542 | 1988-02-29 | ||
US030,764 | 1993-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1988007371A2 true WO1988007371A2 (en) | 1988-10-06 |
WO1988007371A3 WO1988007371A3 (en) | 1988-12-01 |
Family
ID=26706437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1988/001036 WO1988007371A2 (en) | 1987-03-25 | 1988-03-25 | Prevention and treatment of the deleterious effects of exposing skin to the sun, and compositions therefor |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0307468A1 (en) |
AU (1) | AU613370B2 (en) |
CA (1) | CA1316827C (en) |
WO (1) | WO1988007371A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4897260A (en) * | 1987-05-22 | 1990-01-30 | The Rockefeller University | Compositions that affect suppression of cutaneous delayed hypersensitivity and products including same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2264003A1 (en) * | 1972-12-22 | 1974-07-04 | Schering Ag | Pregnane-21-carboxylic acid derivs. - with local (not systemic) anti-inflammatory activity |
US4282216A (en) * | 1977-04-20 | 1981-08-04 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4185100A (en) * | 1976-05-13 | 1980-01-22 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
-
1988
- 1988-03-25 CA CA000562419A patent/CA1316827C/en not_active Expired - Fee Related
- 1988-03-25 WO PCT/US1988/001036 patent/WO1988007371A2/en not_active Application Discontinuation
- 1988-03-25 AU AU17077/88A patent/AU613370B2/en not_active Ceased
- 1988-03-25 EP EP19880904039 patent/EP0307468A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2264003A1 (en) * | 1972-12-22 | 1974-07-04 | Schering Ag | Pregnane-21-carboxylic acid derivs. - with local (not systemic) anti-inflammatory activity |
US4282216A (en) * | 1977-04-20 | 1981-08-04 | Johnson & Johnson | Topical anti-inflammatory drug therapy |
Non-Patent Citations (9)
Title |
---|
British Journal of Dermatology, vol. 115, no. 4, 1986, P.M. Farr et al.: "A quantitative study of the effect of topical indomethacin on cutaneous erythema induced by UVB and UVC radiation", pages 453-466 * |
Cancer Research, vol. 42, no. 10, October 1982, N.J. Lowe et al.: "Inhibition of ultraviolet-B epidermal ornithine decarboxylase induction and skin carcinogenesis in hairless mice by topical indomethacin and triamcinolone acetonide" pages 3941-3943 * |
Drug Intelligence and Clinical Pharmacy, vol. 20, no. 6, June 1986, P. Tan et al.: "Effect of topically applied flurbiprofen on ultraviolet-induced erythema", pages 496-499 * |
Endocrinology, vol. 116, no. 1, 1985, The Endocrine Society (US), J. Gorsline et al.: "Triamcinolone acetonide 21-oic acid methyl ester: a potent local antiinflammatory steroid without detectable systemic effects", pages 263-273 * |
The Journal of Investigative Dermatology, vol. 64, no. 5, 1975, The William & Wilkins Co. (US), D.S. Snyder: "Cutaneous effects of topical indomethacin, an inhibitor of prostaglandin synthesis, on UV-damaged skin", pages 322-325 * |
The Journal of Investigative Dermatology, vol. 77, no. 1, 1981, The William & Wilkens Co. (US), N.J. Lowe: "Ultraviolet light and epidermal polyamines", pages 147-153 * |
The Journal of Investigative Dermatology, vol. 90, no. 3, 1988, The Society for Investigative Dermatology, Inc., P.M. Ross et al.: "Glucocorticoid effects on contact hypersensitivity and on cutaneous response to ultraviolet light in the mouse", pages 366-371 * |
The Merck Manual of Diagnosis and Therapy, 14th edition, 1982, edited by R. Berkow, published by Merck Sharp & Dohme Research Laboratories (Rahway, New Jersey, US), pages 312 * |
Z. Hautkr., vol. 56, no. 22, 27 May 1981, Grosse Verlag (Berlin, DE), K.P. Jablonski et al.: "Der Einfluss von Azetylsalizylsaure auf die biologische Wirksamkeit von UV-A-Strahlen", pages 1437-1446 * |
Also Published As
Publication number | Publication date |
---|---|
CA1316827C (en) | 1993-04-27 |
EP0307468A1 (en) | 1989-03-22 |
AU1707788A (en) | 1988-11-02 |
AU613370B2 (en) | 1991-08-01 |
WO1988007371A3 (en) | 1988-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US4897260A (en) | Compositions that affect suppression of cutaneous delayed hypersensitivity and products including same | |
CA2301009C (en) | Skin care compositions and use | |
US5654312A (en) | Treatment of inflammatory and/or autoimmune dermatoses with thalidomide alone or in combination with other agents | |
Daman et al. | Treatment of alopecia areata with dinitrochlorobenzene | |
US4871752A (en) | Use of aryloxycarboxylic acid derivatives against dermatological diseases | |
CZ20023854A3 (en) | Topic composition for treating psoriasis and related skin diseases | |
CA2076699A1 (en) | Compositions for topical treatment of psoriasis and atopic dermatitis | |
JP2001521901A (en) | Anti-mutagenic composition for treatment and prevention of skin photodamage | |
KR20000036019A (en) | Topical composition and method for enhancing lipid barrier synthesis | |
AU597144B2 (en) | Use of tin protoporphyrin and tin mesoporphyrin in the treatment of psoriasis | |
Fisher et al. | Topical antipsoriatic agents and epidermal mitosis in man | |
AU613370B2 (en) | Prevention and treatment of the deleterious effects of exposing skin to the sun, and compositions therefor | |
US20050101632A1 (en) | Method for the treatment of inflammation | |
US4520132A (en) | Use of undecylenic acid to treat herpes labialis | |
US4734434A (en) | Method for the treatment of pruritus and composition for the use therein | |
Gruner et al. | Studies on the effects of a high dose UVA-1 radiation therapy on surface markers and function of epidermal Langerhans cells | |
US5977176A (en) | Compositions for the treatment of warts and herpes | |
RU2132183C1 (en) | Ointment for treatment of patient with inflammatory and allergic skin damages | |
KR20210009526A (en) | A skin-care agent containing hyaluronic acid complex | |
USRE32990E (en) | Use of undercylenic acid to treat herpes labialis | |
EP0247900A1 (en) | Topical methotrexate preparation for the treatment of hyperproliferative epithelial disease | |
Xu et al. | Efficacy of bimolane in the Malassezia ovalis model of psoriasis | |
Langner et al. | 13-cis-retinoic acid and tetracycline versus 13-cis-retinoic acid alone in the treatment of nodulocystic acne | |
Ross et al. | Glucocorticoid effects on contact hypersensitivity and on the cutaneous response to ultraviolet light in the mouse | |
EP0607642A1 (en) | Compositions for topical application to the skin for treatment and/or prevention of radiation-induced skin damage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1988904039 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1988904039 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1988904039 Country of ref document: EP |